Safety Adverse Event (SAE) Management During Clinical Trial Conduct
 |
|
The accurate and timely capturing and reporting of serious adverse events is a critical component of a successful trial. Ensuring proper safety reporting procedures to sites, institutional review boards (IRB) and competent regulatory authorities is of utmost importance in protecting subjects/patients as well as the integrity of the clinical study results. Therefore, ongoing safety analyses and reporting are vital and require vigilant attention to ensure all serious adverse events are reported in accordance with regulatory requirements.
At Veristat we work with the sites, monitors, sponsors, and investigators to ensure proper and timely reporting of all safety issues, thus helping ensure the safety of trial volunteers. We provide:
Development of the safety management plan inclusive of outlining the safety management responsibilities between Veristat and the sponsor.
Creation of the pregnancy/safety guidelines and forms to ensure proper reporting of pregnancy and SAEs.
Oversight of the build and maintenance of the safety database based on the requiredments of the study specific protocol (in conjunction with the Data Management team).
|
|
> LEARN MORE ABOUT PHARMACOVIGILANCE AND SAFETY MONITORING
Infographic
Why and When to Hold a Pre-IND Meeting with FDAWhile a pre-IND Meeting with the FDA is optional, the Regulatory team at Veristat highly recommends that all
drug developers planning to submit an IND to the FDA have a ...
Infographic
Similarities and Differences Between the CTA and INDSuppose the goal of a development program is to initiate clinical trials within European member states, the United Kingdom, or North America. In
that case, strategic ...
Case Study
First Gene Therapy Approved in EuropeVeristat was brought in to create and manage a full development program for a gene therapy for a very rare inherited disorder. The work involved charting the course in ...
